ScholarIQanswers from OpenAlex
Thomas Jefferson University Hospital
InstitutionResearch output, impact & collaborations
Thomas Jefferson University Hospital is a institution indexed in ScholarIQ from OpenAlex.
What is known about Thomas Jefferson University Hospital?
ScholarIQrecord summary
Thomas Jefferson University Hospital is a research organisation in Philadelphia, US. OpenAlex records 18,796 works and 1,187,977 citations for it. 5,492 researchers list it as their most recent affiliation.
How many works does Thomas Jefferson University Hospital have?
ScholarIQindexed works
Thomas Jefferson University Hospital has 18,796 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Thomas Jefferson University Hospital have?
ScholarIQcitation count
Thomas Jefferson University Hospital has 1,187,977 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Thomas Jefferson University Hospital?
ScholarIQresearcher count
Thomas Jefferson University Hospital has 5,492 researchers in the ScholarIQ index.
What is the average h-index at Thomas Jefferson University Hospital?
ScholarIQavg h-index
Thomas Jefferson University Hospital has an average h-index of 54 in OpenAlex.
What is the ROR of Thomas Jefferson University Hospital?
ScholarIQror
The ROR for Thomas Jefferson University Hospital is on the source record.
What is the OpenAlex record for Thomas Jefferson University Hospital?
ScholarIQopenalex
The OpenAlex for Thomas Jefferson University Hospital is on the source record.
What is the Wikidata of Thomas Jefferson University Hospital?
ScholarIQwikidata
The Wikidata for Thomas Jefferson University Hospital is on the source record.
Who are the most-cited researchers behind Thomas Jefferson University Hospital?
ScholarIQtop researchers by citations
What are the most-cited papers on Thomas Jefferson University Hospital?
ScholarIQmost cited works
The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After
Claudio Bassi, Giovanni Marchegiani, Christos Dervenis, M. G. Sarr, Mohammad Abu Hilal, Mustapha Adham, Peter Allen, Roland Andersson, Horacio J. Asbun, Marc G. Besselink, Kevin C. Conlon, Marco Del Chiaro, Massimo Falconi, Laureano Fernández‐Cruz, Carlos Fernández‐del Castillo, Abe Fingerhut, Helmut Frieß, Dirk J. Gouma, Thilo Hackert, Jakob R. Izbicki, Keith D. Lillemoe, John P. Neoptolemos, Attila Oláh, Richard D. Schulick, Shailesh V. Shrikhande, Tadahiro Takada, Kyoichi Takaori, William Traverso, C. Vollmer, Christopher L. Wolfgang, Charles J. Yeo, Roberto Salvia, Marcus Büchler
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Mark R. Gilbert, James J. Dignam, Terri S. Armstrong, Jeffrey S. Wefel, Deborah T. Blumenthal, Michael A. Vogelbaum, Howard Colman, Arnab Chakravarti, Stephanie L. Pugh, Minhee Won, Robert Jeraj, Paul D. Brown, Kurt A. Jaeckle, David Schiff, Volker W. Stieber, David Brachman, Maria Werner‐Wasik, Ivo W. Tremont‐Lukats, Erik P. Sulman, Kenneth Aldape, Walter J. Curran, Minesh P. Mehta
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial
David W. Andrews, Charles Scott, Paul W. Sperduto, Adam E. Flanders, Laurie E. Gaspar, Michael C. Schell, Maria Werner‐Wasik, William F. Demas, Janice Ryu, Jean-Paul Bahary, Luís Souhami, Marvin Rotman, Minesh P. Mehta, Walter J. Curran
<i>DPC4</i> Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic Cancer
Christine A. Iacobuzio–Donahue, Baojin Fu, Shinichi Yachida, Mingde Luo, Hisashi Abe, Clark M. Henderson, F Vilardell, Zheng Wang, Jesse W. Keller, Priya R. Banerjee, Joseph M. Herman, John L. Cameron, Charles J. Yeo, Marc K. Halushka, James R. Eshleman, Marian Raben, Alison P. Klein, Ralph H. Hruban, Manuel Hidalgo, Daniel A. Laheru
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial
Ulrich Herrlinger, Theophilos Tzaridis, Frederic Mack, Joachim P. Steinbach, Uwe Schlegel, Michael Sabel, Peter Hau, Rolf‐Dieter Kortmann, Dietmar Krex, Oliver Grauer, Roland Goldbrunner, Oliver Schnell, Oliver Bähr, Martin Uhl, Clemens Seidel, Ghazaleh Tabatabai, Thomas E. Kowalski, Florian Ringel, Friederike Schmidt‐Graf, Bogdana Suchorska, Stefanie Brehmer, Astrid Weyerbrock, Miriam Renovanz, Lars Bullinger, Norbert Galldiks, Peter Vajkoczy, Martin Misch, Hartmut Vatter, Moritz Stuplich, Niklas Schäfer, Sied Kebir, Johannes Weller, Christina Schaub, Walter Stummer, Jörg‐Christian Tonn, Matthias Simon, Vera C. Keil, Michael Nelles, Horst Urbach, Martin Coenen, Wolfgang Wick, Michael Weller, Rolf Fimmers, Matthias Schmid, Elke Hattingen, Torsten Pietsch, Christoph Coch, Martin Glas
How much of the research on Thomas Jefferson University Hospital is open access?
ScholarIQopen access share
58%OPEN ACCESS